Medical AI and Semaglutide Implant Highlight Health Tech Advances in Brazil and Canada

Dr. Marcelo Ferraz, a physician specializing in atherosclerosis, molecular biology and precision medicine, will speak at a free Senac Acre event in Rio Branco, Brazil, on Friday, July 17. The lecture will examine how artificial intelligence, electronic health records and other digital tools are reshaping diagnosis, treatment and patient monitoring, while stressing the need to keep empathy, listening and ethics at the core of care.

In Canada, Vivani Medical is developing a tiny sub‑cutaneous implant that continuously releases the GLP‑1 drug semaglutide for at least six months. Two versions are planned: one aimed at obesity and chronic weight management, the other for type‑2 diabetes. The device is intended to simplify therapy and improve patient adherence by eliminating weekly injections.

Both initiatives illustrate the growing focus on technology‑driven solutions in healthcare and the parallel concern for preserving human‑centered practice.